177 related articles for article (PubMed ID: 21083028)
41. Allogeneic and autologous bone marrow transplantation after consolidation therapy in high-risk acute myeloid leukemia in children. Towards a risk-oriented therapy.
Ortega JJ; Díaz de Heredia C; Olivé T; Bastida P; Llort A; Armadans L; Torrabadella M; Massuet L
Haematologica; 2003 Mar; 88(3):290-9. PubMed ID: 12651268
[TBL] [Abstract][Full Text] [Related]
42. Maintenance therapy with histamine plus IL-2 induces a striking expansion of two CD56bright NK cell subpopulations in patients with acute myeloid leukemia and supports their activation.
Cuapio A; Post M; Cerny-Reiterer S; Gleixner KV; Stefanzl G; Basilio J; Herndlhofer S; Sperr WR; Brons NH; Casanova E; Zimmer J; Valent P; Hofer E
Oncotarget; 2016 Jul; 7(29):46466-46481. PubMed ID: 27341131
[TBL] [Abstract][Full Text] [Related]
43. IDA-FLAG regimen for the therapy of primary refractory and relapse acute leukemia: a single-center experience.
Yavuz S; Paydas S; Disel U; Sahin B
Am J Ther; 2006; 13(5):389-93. PubMed ID: 16988532
[TBL] [Abstract][Full Text] [Related]
44. Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720.
Baer MR; George SL; Caligiuri MA; Sanford BL; Bothun SM; Mrózek K; Kolitz JE; Powell BL; Moore JO; Stone RM; Anastasi J; Bloomfield CD; Larson RA
J Clin Oncol; 2008 Oct; 26(30):4934-9. PubMed ID: 18591543
[TBL] [Abstract][Full Text] [Related]
45. Histamine and cytokine therapy.
Hellstrand K; Hermodsson S; Naredi P; Mellqvist UH; Brune M
Acta Oncol; 1998; 37(4):347-53. PubMed ID: 9743456
[TBL] [Abstract][Full Text] [Related]
46. Maintenance therapy in AML: The past, the present and the future.
Molica M; Breccia M; Foa R; Jabbour E; Kadia TM
Am J Hematol; 2019 Nov; 94(11):1254-1265. PubMed ID: 31429099
[TBL] [Abstract][Full Text] [Related]
47. Role of natural killer cell subsets and natural cytotoxicity receptors for the outcome of immunotherapy in acute myeloid leukemia.
Martner A; Rydström A; Riise RE; Aurelius J; Anderson H; Brune M; Foà R; Hellstrand K; Thorén FB
Oncoimmunology; 2016; 5(1):e1041701. PubMed ID: 26942055
[TBL] [Abstract][Full Text] [Related]
48. Anti-Leukemic Properties of Histamine in Monocytic Leukemia: The Role of NOX2.
Kiffin R; Grauers Wiktorin H; Nilsson MS; Aurelius J; Aydin E; Lenox B; Nilsson JA; Ståhlberg A; Thorén FB; Hellstrand K; Martner A
Front Oncol; 2018; 8():218. PubMed ID: 29967760
[TBL] [Abstract][Full Text] [Related]
49. Addressing the incremental benefit of histamine dihydrochloride when added to interleukin-2 in treating acute myeloid leukemia: a Bayesian meta-analysis.
Berry SM; Broglio KR; Berry DA
Cancer Invest; 2011 May; 29(4):293-9. PubMed ID: 21469978
[TBL] [Abstract][Full Text] [Related]
50. Remission maintenance in acute myeloid leukemia: impact of functional histamine H2 receptors expressed by leukemic cells.
Aurelius J; Martner A; Brune M; Palmqvist L; Hansson M; Hellstrand K; Thoren FB
Haematologica; 2012 Dec; 97(12):1904-8. PubMed ID: 22689678
[TBL] [Abstract][Full Text] [Related]
51. Assessment of the consistency and robustness of results from a multicenter trial of remission maintenance therapy for acute myeloid leukemia.
Buyse M; Squifflet P; Lucchesi KJ; Brune ML; Castaigne S; Rowe JM
Trials; 2011 Mar; 12():86. PubMed ID: 21429214
[TBL] [Abstract][Full Text] [Related]
52. Histamine dihydrochloride: inhibiting oxidants and synergising IL-2-mediated immune activation in the tumour microenvironment.
Agarwala SS; Sabbagh MH
Expert Opin Biol Ther; 2001 Sep; 1(5):869-79. PubMed ID: 11728221
[TBL] [Abstract][Full Text] [Related]
53. Interleukin-2-induced graft-versus-leukemia for the treatment of AML in a BRCA2 Fanconi anemia patient.
Yeo CJ; Gilman AL
J Pediatr Hematol Oncol; 2014 Mar; 36(2):e78-80. PubMed ID: 23619121
[TBL] [Abstract][Full Text] [Related]
54. Histamine H
Monczor F; Copsel S; Fernandez N; Davio C; Shayo C
Handb Exp Pharmacol; 2017; 241():141-160. PubMed ID: 27316911
[TBL] [Abstract][Full Text] [Related]
55. Two randomised phase II trials of subcutaneous interleukin-2 and histamine dihydrochloride in patients with metastatic renal cell carcinoma.
Donskov F; Middleton M; Fode K; Meldgaard P; Mansoor W; Lawrance J; Thatcher N; Nellemann H; von der Maase H
Br J Cancer; 2005 Oct; 93(7):757-62. PubMed ID: 16136045
[TBL] [Abstract][Full Text] [Related]
56. Impact of NK Cell Activating Receptor Gene Variants on Receptor Expression and Outcome of Immunotherapy in Acute Myeloid Leukemia.
Hussein BA; Hallner A; Wennström L; Brune M; Martner A; Hellstrand K; Bernson E; Thorén FB
Front Immunol; 2021; 12():796072. PubMed ID: 34956230
[TBL] [Abstract][Full Text] [Related]
57. Histamine as an adjunct to immunotherapy.
Naredi P
Semin Oncol; 2002 Jun; 29(3 Suppl 7):31-4. PubMed ID: 12068386
[TBL] [Abstract][Full Text] [Related]
58. Complete remission after the first cycle of induction chemotherapy determines the clinical efficacy of relapse-preventive immunotherapy in acute myeloid leukaemia.
Nilsson MS; Hallner A; Brune M; Nilsson S; Thorén FB; Martner A; Hellstrand K
Br J Haematol; 2020 Feb; 188(4):e49-e53. PubMed ID: 31853942
[No Abstract] [Full Text] [Related]
59. High-dose recombinant interleukin-2 and acute myeloid leukemias in relapse.
Maraninchi D; Blaise D; Viens P; Brandely M; Olive D; Lopez M; Sainty D; Marit G; Stoppa AM; Reiffers J
Blood; 1991 Nov; 78(9):2182-7. PubMed ID: 1932739
[TBL] [Abstract][Full Text] [Related]
60. Individual patient data meta-analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance therapy in acute myeloid leukemia.
Buyse M; Squifflet P; Lange BJ; Alonzo TA; Larson RA; Kolitz JE; George SL; Bloomfield CD; Castaigne S; Chevret S; Blaise D; Maraninchi D; Lucchesi KJ; Burzykowski T
Blood; 2011 Jun; 117(26):7007-13. PubMed ID: 21518931
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
